Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests
On September 8, Spyre Therapeutics (NASDAQ:SYRE) announced that SPY003, its anti-IL-23 antibody, hit its primary endpoint in Part A of the Phase 2 SKYLINE trial, posting a 10.0-point reduction in Robart...









